Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Ocular Inflammation

  • Home
  • Ocular Inflammation
Ocular Inflammation Linked to Higher Risk of Anti-Adalimumab Antibodies in Autoimmune Disease Patients
Posted innews Ophthalmology Rheumatology

Ocular Inflammation Linked to Higher Risk of Anti-Adalimumab Antibodies in Autoimmune Disease Patients

Posted by MedXY By MedXY 05/29/2026
Ocular inflammation was linked to a higher risk of anti-adalimumab antibody formation in patients treated with adalimumab. More than 20% developed antibodies, supporting closer monitoring and therapeutic drug testing in high-risk patients.
Read More
Clobetasol Propionate Ophthalmic Suspension 0.05%: A New Therapeutic Milestone in Post-Cataract Surgery Inflammation and Pain Management
Posted inClinical Updates news Ophthalmology

Clobetasol Propionate Ophthalmic Suspension 0.05%: A New Therapeutic Milestone in Post-Cataract Surgery Inflammation and Pain Management

Posted by MedXY By MedXY 05/11/2026
This review synthesizes clinical evidence for CPN 0.05% (BYQLOVI®), highlighting its rapid efficacy, superior pain resolution, and favorable safety profile compared to traditional ocular steroids following cataract surgery.
Read More
  • Enhanced Detection of Clinically Significant Prostate Cancer: Insights from the Stockholm3-MRI Screening Study Two-Year Follow-up
  • Fecal Calprotectin as a Biomarker for Diagnosis and Monitoring of Gastrointestinal Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation
  • Enhancing Acute Myeloid Leukemia Treatment: Dual CDK2 and CDK4/6 Inhibition Targets Cell Cycle and Rb/E2F Signaling
  • Unraveling Molecular Mechanisms in Chronic Myeloid Leukemia: Insights from the EURO-SKI Biomarker Study on Treatment-Free Remission and Relapse
  • α-Gal Sensitization as a Cause of Severe Allergic Reactions in Group O Recipients of Group B/AB Plasma and Platelets
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in